Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus

  • Authors:
    • Hiroaki Nagano
    • Shogo Kobayashi
    • Shigeru Marubashi
    • Hiroshi Wada
    • Hidetoshi Eguchi
    • Masahiro Tanemura
    • Yoshito Tomimaru
    • Koji Umeshita
    • Yuichiro Doki
    • Masaki Mori
  • View Affiliations

  • Published online on: October 5, 2012     https://doi.org/10.3892/etm.2012.736
  • Pages: 3-10
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The efficacy of combination therapy with subcutaneous interferon (IFN)-α and intra-arterial 5-fluorouracil (5-FU) as a postoperative adjuvant for resectable advanced hepatocellular carcinoma (HCC) invading the major branches of the portal vein (PVTT) was examined. The prognosis of HCC with PVTT (Vp3 or 4) is extremely poor. Recently, we reported the possibility of combination therapy with IFN-α and intra-arterial 5-FU for intractable HCC with PVTT as a postoperative adjuvant and this is the second report. Patients with HCC with PVTT were included (n=50). Thirty consecutive patients with HCC and PVTT were treated with 3 cycles of a combination therapy consisting of arterial 5-FU infusion (300 mg/mm3/day, 5 days/week, for the initial 2 weeks) and IFN subcutaneous injection (5 MIU, 3 times/week, 4 weeks) as a postoperative adjuvant following hepatic resection; another 20 patients receiving no IFN/5-FU chemotherapy acted as controls. Results for the IFN/5-FU adjuvant treatment group were as follows: disease-free survival (n=9, 15-109 months), survival with recurrence (n=6, 30-92 months), cancer death (n=9, 14-60 months), death from other causes but no recurrence (n=5, 13-87 months) and death from other causes with recurrence (n=1, 22 months). The 1-year survival rate was 100% in patients treated with IFN/5-FU, and 30% in those without IFN/5-FU as historical controls (n=20). There was a significant difference in disease-free and overall survival rates between the two groups (P<0.0001). In conclusion, IFN/5-FU combination therapy may be a very promising postoperative adjuvant treatment for HCC with PVTT.

References

1 

Arii S, Monden K, Niwano M, et al: Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg. 5:86–92. 1998. View Article : Google Scholar

2 

Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI

3 

Kudo M and Okanoue T: Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 72(Suppl 1): S2–S15. 2007. View Article : Google Scholar : PubMed/NCBI

4 

Chung YH, Song IH, Song BC, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 88:1986–1991. 2000. View Article : Google Scholar

5 

Kaneko S, Urabe T and Kobayashi S: Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology. 62(Suppl 1): S69–S73. 2002. View Article : Google Scholar

6 

Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 21:421–427. 2003. View Article : Google Scholar : PubMed/NCBI

7 

Obi S, Yoshida H, Toune R, et al: Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 106:1990–1997. 2006. View Article : Google Scholar

8 

Uka K, Aikata H, Takaki S, et al: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int. 27:1209–1216. 2007.

9 

Sakon M, Nagano H, Dono K, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 94:435–442. 2002.

10 

Ota H, Nagano H, Sakon M, et al: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer. 93:57–64. 2005.

11 

Nagano H, Wada H, Kobayashi S, et al: Long-term outcome of combined subcutaneous interferon-α and intra-arterial 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. (In Press).

12 

Eguchi H, Nagano H, Yamamoto H, et al: Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res. 6:2881–2890. 2000.

13 

Yamamoto T, Nagano H, Sakon M, et al: Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to anti-tumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res. 10:7884–7895. 2004. View Article : Google Scholar

14 

Kondo M, Nagano H, Wada H, et al: Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res. 11:1277–1286. 2005.PubMed/NCBI

15 

Nakamura M, Nagano H, Sakon M, et al: Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol. 46:77–88. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer. 100:1647–1658. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Wada H, Nagano H, Yamamoto H, et al: Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer. 9:361–372. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Tomimaru Y, Eguchi H, Wada H, et al: Insulin-like growth factor-binding protein 7 alters the aensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer. 102:1483–1490. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Tomimaru Y, Eguchi H, Nagano H, et al: MicroRNA-21 induces resistance to the anti-tumor effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 103:1617–1626. 2010.PubMed/NCBI

20 

Nagano H, Sakon M, Eguchi H, et al: Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology. 54:172–179. 2007.PubMed/NCBI

21 

Nagano H, Miyamoto A, Wada H, et al: Interferon-α and 5-fluorouracil combination therapy following palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk and multiple nodules. Cancer. 110:2493–2501. 2007.

22 

The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 5th edition. Liver Cancer Study Group of Japan; 2008

23 

Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI

24 

Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar

25 

Ikai I, Arii S, Ichida T, et al: Report of the 16th follow-up survey of primary liver cancer. The Liver Cancer Study Group of Japan Hepatol Res. 32:163–172. 2005.PubMed/NCBI

26 

Yamakado K, Tanaka N, Nakatsuka A, et al: Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol. 30:660–668. 1999. View Article : Google Scholar : PubMed/NCBI

27 

Cancer of the Liver Italian Program (CLIP) investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 28:751–755. 1998. View Article : Google Scholar : PubMed/NCBI

28 

Asahara T, Itamoto T, Katayama K, et al: Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculature. Hepatogastroenterology. 46:1862–1869. 1999.PubMed/NCBI

29 

Ohkubo T, Yamamoto J, Sugawara Y, et al: Surgical results for hepatocellular carcinoma with macroscopic portal vein thrombosis. J Am Coll Surg. 191:657–660. 2000. View Article : Google Scholar : PubMed/NCBI

30 

Furuse J, Iwasaki M, Yoshino M, et al: Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology. 204:787–790. 1997. View Article : Google Scholar : PubMed/NCBI

31 

Lee HS, Kim JS, Choi IJ, et al: The safety and efficacy of trans-catheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer. 79:2087–2094. 1997. View Article : Google Scholar : PubMed/NCBI

32 

Poon RT, Ng KK, Lam CM, et al: Learning curve for radio-frequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg. 239:441–449. 2004.PubMed/NCBI

33 

Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:693–700. 1996. View Article : Google Scholar : PubMed/NCBI

34 

Poon RT, Fan ST, Ng IO and Wong J: Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg. 237:376–383. 2003. View Article : Google Scholar : PubMed/NCBI

35 

Ikai I, Yamaoka Y, Yamamoto Y, et al: Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis proposal as a standard therapy. Ann Surg. 227:433–439. 1998. View Article : Google Scholar : PubMed/NCBI

36 

Shi J, Lai ECH, Li N, et al: Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 17:2073–2080. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Tazawa J, Maeda M, Sakai Y, et al: Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol. 16:660–665. 2001. View Article : Google Scholar : PubMed/NCBI

38 

Ishikura S, Ogino T, Furuse J, et al: Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol. 25:189–193. 2002. View Article : Google Scholar : PubMed/NCBI

39 

Minagawa M, Makuuchi M, Takayama T and Ohtomo K: Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 233:379–384. 2001. View Article : Google Scholar : PubMed/NCBI

40 

Peng BG, He Q, Li JP and Zhou F: Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 198:313–318. 2009. View Article : Google Scholar

41 

Nakamura M, Nagano H, Marubashi S, et al: A pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer. 112:1765–1771. 2008. View Article : Google Scholar

42 

Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327. 2008. View Article : Google Scholar : PubMed/NCBI

43 

Yang ZF, Poon RT, Liu Y, et al: High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. Mol Cancer Ther. 5:2261–2270. 2006. View Article : Google Scholar : PubMed/NCBI

44 

Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 27:3027–3035. 2009. View Article : Google Scholar : PubMed/NCBI

45 

Murakami M, Kobayashi S, Marubashi S, et al: Tyrosine kinase inhibitor PTK/ZK enhances the anti-tumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 18:589–596. 2011.PubMed/NCBI

Related Articles

Journal Cover

January 2013
Volume 5 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nagano, H., Kobayashi, S., Marubashi, S., Wada, H., Eguchi, H., Tanemura, M. ... Mori, M. (2013). Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Experimental and Therapeutic Medicine, 5, 3-10. https://doi.org/10.3892/etm.2012.736
MLA
Nagano, H., Kobayashi, S., Marubashi, S., Wada, H., Eguchi, H., Tanemura, M., Tomimaru, Y., Umeshita, K., Doki, Y., Mori, M."Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus". Experimental and Therapeutic Medicine 5.1 (2013): 3-10.
Chicago
Nagano, H., Kobayashi, S., Marubashi, S., Wada, H., Eguchi, H., Tanemura, M., Tomimaru, Y., Umeshita, K., Doki, Y., Mori, M."Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus". Experimental and Therapeutic Medicine 5, no. 1 (2013): 3-10. https://doi.org/10.3892/etm.2012.736